Although the incidence of HER2 mutation in EGFR/KRAS wild-type NSCLC patients in this study was similar to others in white patients, there is a difference regarding the frequencies of different mutation subtypes. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.